Heather Wakelee, MD

Articles

Molecular Testing in Early NSCLC to Guide Treatment Decision Making

October 5th 2022

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)

October 5th 2022

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

Looking Toward the Future Management of Non–Small Cell Lung Cancer

August 16th 2022

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations

August 16th 2022

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Novel Therapy for NSCLC With ALK Rearrangements

August 9th 2022

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Novel Therapy for NSCLC With KRAS G12C Mutation

August 9th 2022

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation

August 2nd 2022

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?

August 2nd 2022

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Selecting Therapy for Advanced NSCLC With EGFR Mutations

July 26th 2022

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

Dr. Wakelee on Importance of NGS Testing in NSCLC

March 12th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.

Dr. Wakelee on Unmet Needs for Immunotherapy in NSCLC

March 6th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

January 27th 2019

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Wakelee Discusses Dacomitinib in EGFR+ NSCLC

September 8th 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLC

July 28th 2018

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Dr. Wakelee on Available Treatments Following Tumor Progression in Lung Cancer

March 27th 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses available treatment for patients with lung cancer who progress without a T790M mutation.

Dr. Wakelee Discusses EGFR TKIs in Lung Cancer

March 21st 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses EGFR tyrosine kinase inhibitors (TKIs) in lung cancer.

Dr. Wakelee on First-Line Therapy for EGFR-Mutant Lung Cancer

March 12th 2018

Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.

The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?

January 1st 2018

With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.

Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

December 7th 2016

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.